Biotech entity
FDA is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in fda-approval, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Aug 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in fda-approval, which accounts for 2 of those 3, with the remainder spread across 1 other category. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. The 159-day window averages about 0.1 stories each week. At 6, the average consequence score sits below the same-window beat average of 6.1. Revolution Medicines appears in 3 tracked Biotech stories published from March 22, 2026 through August 27, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 373 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Revolution Medicines. Shared-story counts are live from our verified record — not editorial picks.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
For biotech and pharma professionals, Revolution Medicines' daraxonrasib becomes the first approved multi-RAS inhibitor, with Phase 3 median overall survival of 13.2 months vs 6.6 on chemo, validating the RAS(ON) platform and opening a new commercial front in pancreatic cancer.
Source: ABCNews (US) · Madeline Halpert (gb)
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Revolution Medicines is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
